Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Capital Expenditures for 18 consecutive years, with $34.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 142.64% year-over-year to $34.7 million; the trailing twelve-month figure through Jun 2026 stood at $91.9 million (up 151.57% YoY), and the FY2025 full-year result was $58.7 million, up 71.24% from the prior year.
• Capital Expenditures advanced to $34.7 million in Q2 2026 per ALNY's latest filing, from $21.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $34.7 million in Q2 2026 and bottomed at $4.2 million in Q3 2024.
• Historically, Capital Expenditures has averaged $15.8 million across 5 years, with a median of $15.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures sank 75.47% in 2024, then jumped 189.65% in 2025.
• Over 5 years, Capital Expenditures stood at $21.6 million in 2022, then retreated by 29.24% to $15.3 million in 2023, then slumped by 40.6% to $9.1 million in 2024, then soared by 156.12% to $23.3 million in 2025, then jumped by 48.89% to $34.7 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $34.7 million, $21.8 million, and $23.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.